Lantern Pharma
Lantern Pharma is an AI-driven oncology biotech company dedicated to transforming cancer drug discovery and development. Utilizing its proprietary AI platform, RADR®, the company accelerates the development of targeted cancer therapies, especially for rare and unmet clinical needs. Its innovative approach includes drug repositioning, rescue of failed drugs, and precision trials to improve patient outcomes while reducing costs and timelines. Lantern Pharma actively manages a robust patent portfolio and shares scientific research through publications, posters, and collaborations.
Industries
Nr. of Employees
small (1-50)
Lantern Pharma
Dallas, Texas, United States, North America
Products
LP-300 in Clinical Trials
LP-300 is in Phase 2 clinical testing for never smokers with non-small cell lung cancer (NSCLC). The trial is a multicenter, open-label study evaluating LP-300 in combination with carboplatin and pemetrexed.
LP-184 in Clinical Trials
LP-184 is in Phase 1A clinical trial for advanced or metastatic solid tumors and unresectable or recurrent glioblastoma (GBM).
LP-284 in Clinical Trials
LP-284 is in Phase 1 clinical trial for relapsed or refractory non-Hodgkin’s lymphoma and solid tumors.
LP-300 in Clinical Trials
LP-300 is in Phase 2 clinical testing for never smokers with non-small cell lung cancer (NSCLC). The trial is a multicenter, open-label study evaluating LP-300 in combination with carboplatin and pemetrexed.
LP-184 in Clinical Trials
LP-184 is in Phase 1A clinical trial for advanced or metastatic solid tumors and unresectable or recurrent glioblastoma (GBM).
LP-284 in Clinical Trials
LP-284 is in Phase 1 clinical trial for relapsed or refractory non-Hodgkin’s lymphoma and solid tumors.